OBJECTIVES: (1) To assess the overall performance of the Hospital Anxiety and Depression Scale (HADS) as a screening instrument to identify cases of major depressive disorder (MDD) in mixed cancer outpatients. (2) To determine the sensitivity and specificity of various HADS cut-off scores. (3) To recommend an optimal HADS cut-off score for use in this population. METHODS: A cross-sectional questionnaire and interview survey of consecutive patients attending outpatient clinics in a regional cancer centre in Edinburgh, Scotland, United Kingdom. RESULTS: Thirty (8.3%) of 361 patients met criteria for MDD at interview. With the use of the total HADS score to identify these cases of MDD, the area under the receiver operating characteristic curve was 0.94 (95% CI, 0.91-0.97). A cut-off of 14/15 gave a sensitivity of 0.87 (95% CI, 0.70-0.95), a specificity of 0.85 (95% CI, 0.81-0.89), and a positive predictive value of 0.35, and was considered optimal. CONCLUSION: The HADS can be used effectively as an initial screening tool for the detection of MDD in outpatients attending mixed cancer clinics.
OBJECTIVES: (1) To assess the overall performance of the Hospital Anxiety and Depression Scale (HADS) as a screening instrument to identify cases of major depressive disorder (MDD) in mixed cancer outpatients. (2) To determine the sensitivity and specificity of various HADS cut-off scores. (3) To recommend an optimal HADS cut-off score for use in this population. METHODS: A cross-sectional questionnaire and interview survey of consecutive patients attending outpatient clinics in a regional cancer centre in Edinburgh, Scotland, United Kingdom. RESULTS: Thirty (8.3%) of 361 patients met criteria for MDD at interview. With the use of the total HADS score to identify these cases of MDD, the area under the receiver operating characteristic curve was 0.94 (95% CI, 0.91-0.97). A cut-off of 14/15 gave a sensitivity of 0.87 (95% CI, 0.70-0.95), a specificity of 0.85 (95% CI, 0.81-0.89), and a positive predictive value of 0.35, and was considered optimal. CONCLUSION: The HADS can be used effectively as an initial screening tool for the detection of MDD in outpatients attending mixed cancer clinics.
Authors: Shabbir M H Alibhai; Sara O'Neill; Karla Fisher-Schlombs; Henriette Breunis; Joseph M Brandwein; Narhari Timilshina; George A Tomlinson; Heidi D Klepin; S Nicole Culos-Reed Journal: Leuk Res Date: 2012-06-21 Impact factor: 3.156
Authors: Sylvie D Lambert; Julie F Pallant; Kerrie Clover; Benjamin Britton; Madeleine T King; Gregory Carter Journal: Qual Life Res Date: 2014-04-01 Impact factor: 4.147
Authors: Tim Luckett; Phyllis N Butow; Madeleine T King; Mayumi Oguchi; Gaynor Heading; Nadine A Hackl; Nicole Rankin; Melanie A Price Journal: Support Care Cancer Date: 2010-07-02 Impact factor: 3.603
Authors: Vanessa L Beesley; Matthew Burge; Monica Dumbrava; Jack Callum; Rachel E Neale; David K Wyld Journal: Support Care Cancer Date: 2018-03-29 Impact factor: 3.603
Authors: Christian J Nelson; Christina Cho; Alexandra R Berk; Jimmie Holland; Andrew J Roth Journal: J Clin Oncol Date: 2009-12-07 Impact factor: 44.544
Authors: Alasdair G Rooney; Shanne McNamara; Mairi Mackinnon; Mary Fraser; Roy Rampling; Alan Carson; Robin Grant Journal: Neuro Oncol Date: 2012-12-09 Impact factor: 12.300
Authors: Talia R Weiss Wiesel; Christian J Nelson; William P Tew; Molly Hardt; Supriya Gupta Mohile; Cynthia Owusu; Heidi D Klepin; Cary P Gross; Ajeet Gajra; Stuart M Lichtman; Rupal Ramani; Vani Katheria; Laura Zavala; Arti Hurria Journal: Psychooncology Date: 2014-08-06 Impact factor: 3.894
Authors: K Kirchheiner; A Czajka; E Ponocny-Seliger; E Komarek; G Hohenberg; R Pötter; W Dörr Journal: Strahlenther Onkol Date: 2013-05-25 Impact factor: 3.621